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Abstract
Objective: To prospectively evaluate growth parameters assessed by weight and
length in infected and uninfected infants born to HIV-1-infected mothers and
followed from birth to 18 months.
Methods: A cohort consisting of ninety-seven uninfected and forty-two infected
infants born to HIV-infected mothers enrolled from 1995 to 2004, and admitted
during their first 3 months of life at a referral Pediatric AIDS Clinic in Belo Hor-
izonte, Brazil. Infants were followed until 18 months of age. Data were analysed
using mixed-effects linear regression models for weight and length fitted by
restricted maximum likelihood.
Results: Infected infants contributed to 466 weight and 411 recumbent length
measurements. Uninfected infants provided 924 weight and 907 length mea-
surements. Mean birth weight and length were similar in both groups, 3?1 (SD 0?4)
and 3?0 (SD 0?5) kg, and 48?7 (SD 1?4) and 48?8 (SD 2?9) cm for uninfected and
infected infants, respectively. However, HIV-1 infection had an early impact in
growth impairment: at 6 months of age, HIV-infected children were 1 kg lighter
and 2 cm shorter than the uninfected.
Conclusions: Growth faltering in weight, but not length, in HIV-infected
children in Brazil is more marked than that reported in a European cohort,
probably reflecting background nutritional deficiencies and concomitant infec-
tions. In these settings, early and aggressive nutritional management in HIV-1-
infected infants should be a priority intervention associated with the antiretroviral
therapy.
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The HIV epidemic began in Brazil in the 1980s and by the
end of 2003 UNAIDS estimated that 660 000 Brazilians had
already been infected with the virus(1), corresponding to
40?5% of the total HIV-infected population of Latin
America. Between 1980 and 2005 the number of AIDS
cases reported to the Brazilian Ministry of Health was
371 827(2), of which 9965 (2?7%) were perinatally infected
children. Antiretroviral therapy (ART) for the prevention
of mother-to-child transmission of HIV-1 (PMTCT) was
introduced in Brazil in 1995, resulting in significant
reduction of transmission rates(2).
The assessment of weight at birth and of child growth
is one of the indicators of their nutritional status. In
developed countries, HIV vertically infected children
present similar weight and length at birth compared to
those of non-infected children(3). Differences in weight
and length growth of infected and uninfected children
start to appear in the first months of life(3,4).
The growth assessment of HIV-infected children is
important both to determine the disease stage and prog-
nosis and to assess the effectiveness and toxicity of ART
regimens and to study the nutritional implications of the
infection(5). Growth seems to be one of the most sensitive
indicators of the disease progression in children living with
HIV/AIDS(6). Even in children who have been using anti-
retroviral drugs, the absence of growth is a poor prognostic
indicator. Weight gain is also an important indicator of ART
effectiveness(7). For these reasons, anthropometric methods
are useful to monitor the disease progression and to assess
response to treatment.
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Studies involving infants born to HIV-1-infected
mothers can provide useful insights into the nutritional
implications of the infection, and can contribute to the
establishment of intervention strategies for this segment
of the population. The objective of the present study was
to prospectively evaluate growth parameters assessed by
weight and recumbent length in infected and uninfected
infants born to HIV-1-infected mothers and followed from
birth to 18 months.
Patients and methods
Study design and population
This cohort study was conducted at the Universidade
Federal de Minas Gerais (UFMG) Pediatric HIV Clinic, in
Belo Horizonte, Brazil. Infants born to HIV-1-infected
mothers from 1995 to 2003 and admitted at the clinic
within the first 3 months of life were eligible to partici-
pate. The subjects were followed up to 18 months of age.
Clinical and laboratory data were collected using stan-
dardised data forms, coded and entered in a database.
The study was approved by the UFMG Ethical Committee.
Determination of HIV infection was based on the
Brazilian National AIDS Program (NAP) algorithm(8):
(i) the existence of two samples, taken after 2 weeks of
life, testing positive for HIV according to a DNA-PCR
(AmplicorR ; Roche, Basel, Switzerland) or an RNA-PCR
(NASBAR ; Organon-Teknica, Boxtel, The Netherlands)
method; (ii) the persistence of HIV antibodies as detected
by ELISA and Western blot after 18 months of age; or
(iii) the development at any age of a clinical condition
compatible with AIDS according to the Centers for
Disease Control and Prevention (CDC)/94 classification
system for infants under 13 years(9). The criteria to
establish the absence of HIV infection were: (i) two
negative HIV DNA-PCR or RNA-PCR samples, taken at
ages 2 weeks to 4 months and 4–6 months; and (ii) two
negative anti-HIV (ELISA) serum tests performed after
6 months of age, with a minimum interval between tests
of 2 months, and the absence of clinical conditions
compatible with AIDS.
Anthropometric measurements
Weight in kilograms and length in centimeters of ninety-
seven HIV-uninfected and forty-two HIV-infected infants
were measured during regular visits by trained paedia-
tricians. The measurements were carried out according
to standard procedures(10). An electronic paediatric scale
(Indu´stria Filizola S/A, Sa˜o Paulo, Brazil), weighing
capacity from 125 g to 15 kg, accuracy of 5 g, was used to
weigh children and body length was measured using a
horizontal wooden stadiometer with the infant in recum-
bent position. Infected and uninfected infants contributed
with 466 weight and 411 length measurements and
924 weight and 907 length measurements, respectively.
The median follow-up times were 15?2 months (range
6?8–18?0 months) and 14?3 months (range 6?3–18?6
months) for the HIV-infected and uninfected infants,
respectively.
Statistical analysis
Statistical analyses were performed using S-Plus 2000(11)
and Stata 6?0(12) software, and in all cases the level of
significance was established at 5%.
The mean values of weights and lengths of the two
groups, taken at the time of birth, were compared using
Student’s t test(13). The distribution of the categorical vari-
ables according to the two clinical groups was evaluated
using the x2 and the Fisher exact tests(13). HIV-infected
children were classified according to the 1994 CDC
classification for children under the age of 13 years(9).
The mixed-effects linear regression models for weight
and stature were fitted using the restricted maximum like-
lihood method. The LME function provided by the S-Plus
2000 software(14) was used in order to find the estimates.
Comparison of the models was based on the Akaike
Information Criteria and on the maximum likelihood ratio
test. The effect of extra random terms was evaluated using
the restricted maximum likelihood ratio test.
The approach described by Diggle et al.(15) was used to
evaluate the covariance structure of the anthropometric
models. The covariates included in the statistical analysis
were exposure to prophylactic ART regimens (15 yes,
05no), gender of child (15male, 05 female), clinical
group (15HIV-infected, 05uninfected), gestational
period (05more than 36 weeks, 15 less than 36 weeks)
and polynomial age (monthsn; n5 1, n5 2).
Based on the values of weight and length, the growth
rates of the different groups of children were obtained
from the final equations produced by the mixed-effects
models. The average growth rates were stratified
according to age groups and compared with those
obtained from the European Collaborative Study(3), using
the large-sample z test.
Results
Premature births, defined as children born before 36
weeks of gestation, were observed only among the HIV-
infected group (22%). There were no significant differ-
ences with respect to birth weight and length between
HIV-uninfected and infected children born at term. The
mean birth weight and length of uninfected children were
3?1 (SD 0?4) kg and 48?7 (SD 1?4) cm. Similarly, infected
children had a mean birth weight of 3?0 (SD 0?5) kg and a
mean length of 48?8 (SD 2?9) cm. Males comprised 54?6%
of the uninfected and 52?4% of the infected population.
Exposure to ART for PMTCT was reported by 91/95
(95?8%) of non-transmitting mothers and by 28/42
(66?7%) of transmitting mothers (P, 0?0001).
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During the follow-up period, ART was initiated in 31
out of the 42 (73?8%) infected children, at a mean age of
8?7 months (range 0?8–17?1). Dual nucleoside analogue
reverse transcriptase inhibitors (NRTI) were the initial
regimen in eleven (35?5%) subjects. Highly active anti-
retroviral therapy (HAART) was used as the initial regi-
men by the remaining twenty (64?5%) subjects. Eighteen
subjects were on a protease inhibitor (PI)-containing
HAART regimen and two on a non-PI HAART regimen
(2 NRTI1 1 non-nucleoside analogue reverse tran-
scriptase inhibitor). There were no changes on the initial
ART regimen during the observation period.
The median age at first visit was 0?9 months (range
0?2–3?5) and 1?7 months (range 0?1–3?5) for uninfected
and infected children, respectively. At admission, most
infected children were asymptomatic (27/42 or 64?3%).
At 1 year of age, 33?3% of the evaluable infected children
presented with category C disease (12/36). During the
follow-up period, mortality rate among the infected
children was 7?1% (95% CI 1?5, 19?5). No deaths were
observed in the uninfected children.
As recommended by the Brazilian NAP(8), artificial
formula feeding was provided free of charge to all HIV-
1-exposed infants for the first 6 months of age, regardless
of their infection status.
Table 1 shows the final models for weight and recum-
bent length. The variable group was included in the model
in order to detect if there were differences between HIV-
infected and uninfected children with respect to weight.
The results show that as length increased, boys became
heavier than girls, while the interaction between length and
age indicates that the effects of length on the weight of the
infants increased with age. Moreover, HIV-infected children
were lighter than the corresponding uninfected children,
and this difference in body weight increased until the end
of the first year of life. At 6 months of age, the average
weight difference between uninfected and infected
children was approximately 1 kg, while at 12 months
the difference was 1?3 kg. The growth rate of infants,
expressed in terms of body weight, decreased as a func-
tion of increasing age (Fig. 1), particularly within the
group of uninfected children: after 12 months of age, the
growth rate within the HIV-infected group was actually
higher than that of the uninfected group.
The variable group was included in the recumbent
length model for the same purpose as in the weight
model. The model presented in Table 1 establishes that
the differences in length between boys and girls increased
with age: thus, at 6 months boys were 2?0 cm taller than
girls, while at 12 months the average difference was
2?8 cm. The interaction between group and age poly-
nomial demonstrates that HIV-infected children were
smaller than uninfected children, on average 2?8 cm
shorter at 6 months. The difference in length between
HIV-infected and uninfected infants increased up to 8
months of age, after which it began to diminish, although
HIV-infected children were always smaller than unin-
fected children. For both groups, the linear growth rate
decreased as a function of increasing age (Fig. 2); the
growth rate of HIV-infected children was lower than that
Table 1 Weight and length models for HIV-infected and uninfected infants of a cohort of Belo Horizonte (Minas Gerais, Brazil), born
between 1995 and 2004
Weight values Length values
Variables b SD 95% CI P b SD 95% CI P
Intercept 22?46 0?39 23?23, 21?69 ,0?0001 48?94 0?33 48?29, 49?60 ,0?0001
Sex 21?01 0?32 21?65, 20?37 0?002 0?51 0?41 20?31, 1?33 0?22
Clinical group 20?14 0?07 20?27, 20?0009 0?048 20?73 0?46 21?64, 0?18 0?12
Stature 0?11 0?008 0?09, 0?12 ,0?0001
Age (month) 1?03 0?06 0?91, 1?16 ,0?0001 3?02 0?09 2?83, 3?20 ,0?0001
Age2 (month2) 20?04 0?006 20?05, 20?03 ,0?0001 20?08 0?006 20?10, 20?07 ,0?0001
Interactions
Clinical group3age 20?19 0?03 20?25, 20?13 ,0?0001 20?52 0?13 20?77, 20?27 ,0?0001
Clinical group3age2 0?008 0?002 0?005, 0?01 ,0?0001 0?03 0?007 0?01, 0?04 0?0003
Sex3 age 0?31 0?12 0?09, 0?54 0?006
Sex3 age2 20?01 0?007 20?03, 20?0008 0?04
Sex3 stature 0?02 0?006 0?01, 0?04 0?0002
Length3age 20?008 0?0009 20?01, 20?006 ,0?0001
Length3age2 0?0004 0?00006 0?0003, 0?0005 ,0?0001
Random effects
Intercept 0?27 2?14
Age 0?14 0?56
Age2 0?006 0?03
Residual 0?31 1?54
Measurements (N) 1?313 1?318
Number of children (n) 139 139
b5 coefficient estimates.
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of uninfected children until 8 months of age and subse-
quently higher.
Table 2 shows the rates of growth of HIV-infected and
uninfected children in this cohort estimated from the
weight and recumbent length models. The information was
compared with the data presented in the European study(3).
Within the age range of 1–24 months, both HIV-infected
and uninfected Brazilian children presented a growth rate
by weight smaller than in the European study. Within the
age range of 1–11 months, the growth rate by length of
uninfected children was higher than that observed in the
European study(3), while within the age range of 12–24
months the growth rate was smaller. The growth rate by
length of HIV-infected children was similar in both cohorts
within the age range of 1–5 months. Within the age range
of 6–24 months, the HIV-infected children in our cohort
presented a growth rate by length higher than that of the
European cohort. However, the comparison between the
two cohorts is limited due to the fact that data in our cohort
were collected only from 0 to 18 months of age.
Discussion
The results of the present study demonstrate that differ-
ences in weight and length between uninfected and HIV-
infected infants emerge at an early age and increase as the
children get older. The growth of HIV-infected children is
clearly affected by the disease, as shown by the differ-
ences in weight (1 kg lighter) and length (2 cm smaller)
of this group compared with uninfected children at
6 months of age.
The catch-up on weight and length seen among the
infected children at the end of first year of life is probably
related to the response to ART. As reported by others,
control of viral replication is associated with sustained
growth(16,17).
With respect to European children, it has previously
been reported that while uninfected and HIV-infected
infants did not present significant weight differences at
the time of birth, the latter group was on average 460 g
lighter at 3 months of age(3). Moreover, the authors
observed that the difference in weight between the two
groups increased with age, confirming similar findings
reported by Berhane et al.(18). In this latter study,
6-month-old HIV-infected children from a Ugandan cohort
were shown to present significantly lower weight and
length than the uninfected group. The authors suggested
that reduced weight and length resulted from general
debilitation produced by frequent opportunistic infections
and the consequent effects on food ingestion, absorption
of nutrients and energy expenditure. Furthermore, there is
evidence in the literature that viral replication itself is
associated with growth impairment(19,20).
Comparing the Belo Horizonte and the European
cohorts(3), it was possible to establish that HIV-infected
and uninfected children of all age groups belonging to
the former presented lower growth rates by weight than
the latter. Within the uninfected group, the growth rate by
length in children up to 11 months old included in the
Belo Horizonte cohort was larger than in the European
cohort, while in children of other age groups the growth
rate was smaller. HIV-infected children up to 5 months
old presented no differences concerning growth rate by
length. Children of the Belo Horizonte cohort within the
age range of 6–12 months presented a larger growth rate
by length than those of the European study(3). It should
be emphasised, however, that the comparison between
children aged between 12 and 24 months must be viewed
with caution, since the follow-up period for the Belo
Horizonte cohort was only 18 months.
In both studies, there were HIV-infected children who
had been treated with ART, as well as those who had not
been so treated. A comparison of the growth rates of
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Fig. 1 Growth rate, expressed in terms of change in weight
(kg/year), of the uninfected (——) and HIV-infected (- - -)
groups within a cohort of infants born between 1995 and 2004
in Belo Horizonte, Minas Gerais, Brazil
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Fig. 2 Growth rate, expressed in terms of change in length
(cm/year), of the uninfected (——) and HIV-infected (- - -)
groups within a cohort of infants born between 1995 and 2004
in Belo Horizonte, Minas Gerais, Brazil
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these two groups indicates that the main problem asso-
ciated with the HIV-infected and uninfected children of
the Belo Horizonte cohort related to factors associated
with gain of body weight. The results of the present
study, when compared with the European cohort, suggest
that HIV-infected children of the Belo Horizonte cohort
were more affected in terms of weight than in terms
of length.
Since there were two types of individuals, i.e. ART
treated and non-treated, within the HIV-infected group,
various stages of the disease along with differential
treatments could be found. Therefore, the diminished
nutritional status observed amongst the HIV-infected
children may be a consequence of the dissimilar progress
of the disease in treated and non-treated children, or it
could be associated with factors that were not evaluated
in the present study (e.g. diminished ingestion of food,
associated infections, secondary effects of medication,
resistance to ART and adherence to treatment).
Since the children of the Belo Horizonte cohort
were regularly followed up in a reputable specialised
HIV centre, and many were born of mothers submitted
to prenatal examination in the same institution, it is
unlikely that these results are a consequence of a selec-
tion bias. The absence of food ingestion, socio-economic
and clinical information in the files of the children
of the Belo Horizonte cohort implied that it was not
possible to establish whether the diminished growth
observed among HIV-infected children was caused by the
reduced ingestion of food and nutrients, side-effects of
medication, associated infections or the evolution of
the disease.
The anthropometric indicators derived from the pre-
sent study suggest the need to identify HIV-infected
children as early as possible and to adopt intervention
strategies related to nutritional input.
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